Consun Pharmaceutical Group Ltd
Company Profile
Business description
Consun Pharmaceutical Group Ltd is a biotechnology company with a modern pharmaceutical enterprise that integrates R&D, production, and marketing. The company has two reportable segments: the Consun pharmaceutical segment, which is the key revenue driver, and makes and sells modern Chinese medicines and medical contrast medium, and the Yulin pharmaceutical segment, which manufactures and sells traditional Chinese medicines. Company derives revenue from kidney medicines, contrast mediums, orthopedics medicines, dermatologic medicines, hepatobiliary medicines, medicines for women and children, and others.
Contact
71, Dongpeng Avenue
Eastern section
Guangzhou Economic and Technological Development
Guangzhou
CHNT: +86 2082264529
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
3,115
Stocks News & Analysis
stocks
Pure-play data center share raises capital to fund AI demand
stocks
Chart of the Week: BHP’s growth story faces a reality check
stocks
3 best ASX growth stocks to buy for the long term
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,962.30 | 50.70 | -0.56% |
| CAC 40 | 8,377.86 | 4.57 | -0.05% |
| DAX 40 | 24,915.49 | 84.04 | -0.34% |
| Dow JONES (US) | 52,552.97 | 105.67 | -0.20% |
| FTSE 100 | 10,572.24 | 56.32 | 0.54% |
| HKSE | 24,514.29 | 494.31 | -1.98% |
| NASDAQ | 25,881.95 | 387.28 | -1.47% |
| Nikkei 225 | 63,583.65 | 3,251.89 | -4.87% |
| NZX 50 Index | 13,620.40 | 5.62 | 0.04% |
| S&P 500 | 7,533.77 | 38.63 | -0.51% |
| S&P/ASX 200 | 8,776.30 | 40.50 | -0.46% |
| SSE Composite Index | 3,818.59 | 63.82 | -1.64% |